Combine scalable analytics with advanced AI capabilities like LLMs and agentic tasks to create a new chipmaking platform.

And that was also presented at ASH 2025 and also a very, very strong data set. I should mention that BI-1808 that was monotherapy, single-agent therapy. Then, we also started our Phase IIa trial ...

This release contains forward-looking statements based on current assumptions and forecasts made by the Group. Various known and unknown risks, uncertainties and other factors could lead to material ...

It's quick and easy to access Live Science Plus, simply enter your email below. We'll send you a confirmation and sign you up for our daily newsletter, keeping you up to date with the latest science ...